Second Primary Malignancies in Gastrointestinal Cancer

Second primary malignancies (SPMs) arise when a patient with a history of one gastrointestinal (GI) cancer develops a new, distinct cancer in the GI tract or elsewhere. Advances in early detection and multimodal therapy have extended survival for patients with gastric and colorectal cancers, leading to a growing population at risk of SPMs. Epidemiological studies indicate that survivors of primary GI malignancies face a modest but significant elevation in risk for subsequent tumours, influenced by patient age, initial tumour characteristics, treatment modalities and genetic predispositions. Common sites for gastrointestinal SPMs include the small intestine, bile ducts and colorectum, while extracolonic SPMs may affect the urinary bladder, female genital tract, kidney and thyroid. A latency period of several years often precedes the appearance of a second tumour, underscoring the necessity for long-term surveillance. Risk stratification and tailored follow-up protocols are essential to identify high-risk individuals and optimise secondary prevention strategies.

Research from Nature Portfolio

Recent studies have provided comprehensive population-based insights into the incidence and determinants of SPMs in GI cancer survivors. A large registry analysis of gastric adenocarcinoma patients diagnosed between 2000 and 2020 employed the SEER database to quantify SPM risk, reporting that 4.3 % of survivors developed a second malignancy with a standardised incidence ratio (SIR) of 1.36 compared to the general population. Older age, male sex, advanced tumour grade and prior radiotherapy or surgery emerged as independent predictors of SPM development, while paradoxically survivors who developed SPMs demonstrated marginally improved overall survival, possibly reflecting lead-time advantages. In colorectal cancer cohorts, a decade-long follow-up of over a thousand patients revealed a 19.9 % prevalence of SPMs, with breast, prostate and kidney cancers among the most frequent extracolonic sites. Early-stage colorectal cancer and absence of relapse were associated with heightened SPM risk, suggesting that longer disease-free intervals confer greater opportunity for second tumours to manifest. These findings reinforce the importance of vigilant, site-specific screening in GI cancer survivors.

Second Primary Malignancies in Gastrointestinal Cancer publication trend

The graph below shows the total number of articles in second primary malignancies in gastrointestinal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Second primary malignancy (SPM): A new, histologically distinct cancer that arises in a patient previously diagnosed with a primary malignancy.

Standardised incidence ratio (SIR): The ratio of observed to expected cases of cancer in a study cohort, adjusted for age and other demographic factors.

Absolute excess risk (AER): The difference between the observed and expected number of cancer cases per population unit, indicating the additional burden attributable to the primary cancer history.

Latency period: The time interval between diagnosis of the primary cancer and the detection of a second primary malignancy.

References

1. Incidence, risk and prognosis of second primary malignancy of patients with gastric adenocarcinoma. Scientific Reports (2024).
2. Second primary malignancies in colorectal cancer patients. Scientific Reports (2021).
3. Risk of extracolonic second primary cancers following a primary colorectal cancer: a systematic review and meta-analysis. International Journal of Colorectal Disease (2022).
4. Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer. Clinical Epidemiology (2021).